Related Experiment Videos
Methotrexate for steroid-resistant systemic lupus erythematosus
M Hashimoto1, S Nonaka, E Furuta
1Department of Clinical Immunology, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan.
Clinical Rheumatology
|June 1, 1994
Summary
Low-dose methotrexate (MTX) effectively treated two patients with steroid-resistant systemic lupus erythematosus (SLE). MTX alleviated symptoms like fever and pancytopenia, offering a safer alternative to high-dose steroids for refractory SLE.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease.
- Steroid-resistant SLE presents a significant treatment challenge.
- Conventional treatments carry substantial risks of adverse effects.